- Home
- KRYS vs ARE Comparison
KRYS vs ARE Comparison
Compare KRYS & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRYS | ARE |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.8B |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | KRYS | ARE |
|---|---|---|
| Price | $319.57 | $43.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | ★ $395.44 | $51.93 |
| AVG Volume (30 Days) | 240.0K | ★ 2.0M |
| Earning Date | 11-02-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 6.82% |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 3.62 | 1.68 |
| Revenue | $389,130,000.00 | ★ $3,026,556,000.00 |
| Revenue This Year | $28.02 | N/A |
| Revenue Next Year | $28.14 | N/A |
| P/E Ratio | $88.79 | ★ $25.12 |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $183.26 | $39.41 |
| 52 Week High | $382.54 | $78.51 |
Technical Indicators
Market Signals| Indicator | KRYS | ARE |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 40.44 |
| Support Level | $318.87 | $41.44 |
| Resistance Level | $376.74 | $55.20 |
| Average True Range (ATR) | 11.07 | 1.64 |
| MACD | -0.32 | -0.07 |
| Stochastic Oscillator | 20.28 | 43.03 |
Price Performance
Historical ComparisonAbout KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.